ORCID as entered in ROS

Select Publications
2025, 'Bivalent mRNA booster vaccination recalls cellular and antibody immunity against antigenically divergent SARS-CoV-2 spike antigens', Npj Vaccines, 10, pp. 74, http://dx.doi.org/10.1038/s41541-025-01129-6
,2025, 'High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection', Nature Communications, 16, pp. 446, http://dx.doi.org/10.1038/s41467-025-55873-3
,2025, 'Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19', Vaccine, 55, pp. 126987, http://dx.doi.org/10.1016/j.vaccine.2025.126987
,2025, 'Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines', Jci Insight, 10, pp. e187075, http://dx.doi.org/10.1172/jci.insight.187075
,2025, 'Macrophages direct location-dependent recall of B cell memory to vaccination', Cell, pp. S0092-8674(25)00407-6, http://dx.doi.org/10.1016/j.cell.2025.04.005
,2025, 'Towards evidence-based immunology', Nature Immunology, http://dx.doi.org/10.1038/s41590-025-02180-0
,2024, 'Defining the correlates of lymphopenia and independent predictors of poor clinical outcome in adults hospitalized with COVID-19 in Australia', Scientific Reports, 14, pp. 11102, http://dx.doi.org/10.1038/s41598-024-61729-5
,2024, 'Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates', Nature Communications, 15, pp. 8395, http://dx.doi.org/10.1038/s41467-024-52194-9
,2024, 'Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia', Pathology, 56, pp. 882 - 888, http://dx.doi.org/10.1016/j.pathol.2024.04.009
,2024, 'Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis', Lancet Microbe, 5, pp. e459 - e467, http://dx.doi.org/10.1016/S2666-5247(23)00398-1
,2023, 'Evidence for exposure dependent carriage of malaria parasites across the dry season: modelling analysis of longitudinal data', Malaria Journal, 22, http://dx.doi.org/10.1186/s12936-023-04461-1
,2023, 'Monoclonal antibody levels and protection from COVID-19', Nature Communications, 14, pp. 4545, http://dx.doi.org/10.1038/s41467-023-40204-1
,2023, 'Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis', Nature Communications, 14, pp. 1633, http://dx.doi.org/10.1038/s41467-023-37176-7
,2023, 'Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis', Lancet Microbe, 4, pp. e883 - e892, http://dx.doi.org/10.1016/S2666-5247(23)00194-5
,2023, 'Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency', Plos Pathogens, 19, pp. e1011755, http://dx.doi.org/10.1371/journal.ppat.1011755
,2023, 'Individual variation in vaccine immune response can produce bimodal distributions of protection', Vaccine, 41, pp. 6630 - 6636, http://dx.doi.org/10.1016/j.vaccine.2023.09.025
,2023, 'Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection', Science Advances, 9, pp. eadg5301, http://dx.doi.org/10.1126/sciadv.adg5301
,2023, 'Predicting the efficacy of variant-modified COVID-19 vaccine boosters', Nature Medicine, 29, pp. 574 - 578, http://dx.doi.org/10.1038/s41591-023-02228-4
,2023, 'Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection', Emerging Infectious Diseases, 29, pp. 381 - 388, http://dx.doi.org/10.3201/eid2902.221422
,2023, 'Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections', JCI Insight, 8, pp. e172470, http://dx.doi.org/10.1172/jci.insight.172470
,2022, 'Population heterogeneity in Plasmodium vivax relapse risk', PLoS Neglected Tropical Diseases, 16, http://dx.doi.org/10.1371/journal.pntd.0010990
,2022, 'Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice', Malaria Journal, 21, pp. 49, http://dx.doi.org/10.1186/s12936-022-04075-z
,2022, 'The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants', Immunity, 55, pp. 1316 - 1326.e4, http://dx.doi.org/10.1016/j.immuni.2022.05.018
,2022, 'Relating in Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial', Clinical Infectious Diseases, 75, pp. E878 - E879, http://dx.doi.org/10.1093/cid/ciac075
,2022, 'Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?', Nature Reviews Immunology, 22, pp. 387 - 397, http://dx.doi.org/10.1038/s41577-022-00716-1
,2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7
,2022, 'Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization', Nature, 602, pp. 654 - 656, http://dx.doi.org/10.1038/s41586-021-04387-1
,2022, 'Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis', Lancet Microbe, 3, pp. e52 - e61, http://dx.doi.org/10.1016/S2666-5247(21)00267-6
,2022, 'Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial', Clinical Infectious Diseases, 75, pp. e878 - e879, http://dx.doi.org/10.1093/cid/ciac075
,2022, 'SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern', , http://dx.doi.org/10.21203/rs.3.rs-1207364/v1
,2021, 'Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19', Nature Communications, 12, pp. 1162, http://dx.doi.org/10.1038/s41467-021-21444-5
,2021, 'Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain', Cell Reports, 37, pp. 109822, http://dx.doi.org/10.1016/j.celrep.2021.109822
,2021, 'Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection', Nature Medicine, 27, pp. 1205 - 1211, http://dx.doi.org/10.1038/s41591-021-01377-8
,2021, 'Decay of Fc-dependent antibody functions after mild to moderate COVID-19', Cell Reports Medicine, 2, pp. 100296, http://dx.doi.org/10.1016/j.xcrm.2021.100296
,2021, 'Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection', Nature Reviews Immunology, 21, pp. 395 - 404, http://dx.doi.org/10.1038/s41577-021-00550-x
,2021, 'Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice', Proceedings of the National Academy of Sciences of the United States of America, 118, pp. e2101918118, http://dx.doi.org/10.1073/pnas.2101918118
,2021, 'SARS-CoV-2 variants: levels of neutralisation required for protective immunity', , pp. 2021.08.11.21261876, http://dx.doi.org/10.1101/2021.08.11.21261876
,2021, 'What level of neutralising antibody protects from COVID-19?', , pp. 2021.03.09.21252641, http://dx.doi.org/10.1101/2021.03.09.21252641
,2020, 'Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models', Nature Reviews Immunology, 20, pp. 727 - 738, http://dx.doi.org/10.1038/s41577-020-00471-1
,2020, 'Influencing public health policy with data-informed mathematical models of infectious diseases: Recent developments and new challenges', Epidemics, 32, pp. 100393, http://dx.doi.org/10.1016/j.epidem.2020.100393
,2020, 'Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption', Proceedings of the Royal Society B: Biological Sciences, 287, pp. 20200354, http://dx.doi.org/10.1098/rspb.2020.0354
,2020, 'Early analysis of the australian covid-19 epidemic', Elife, 9, pp. 1 - 14, http://dx.doi.org/10.7554/ELIFE.58785
,2020, 'Malaria Parasite Clearance: What Are We Really Measuring?', Trends in Parasitology, 36, pp. 413 - 426, http://dx.doi.org/10.1016/j.pt.2020.02.005
,2019, 'Predictors of SIV recrudescence following antiretroviral treatment interruption', Elife, 8, pp. e49022, http://dx.doi.org/10.7554/eLife.49022
,2019, 'Corrigendum: Defining the effectiveness of antimalarial chemotherapy: Investigation of the lag in parasite clearance following drug administration (Journal of Infectious Diseases (2016) 214 (753-761) DOI: 10.1093/infdis/jiw234)', Journal of Infectious Diseases, 219, pp. 1852 - 1853, http://dx.doi.org/10.1093/infdis/jiy729
,2019, 'Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells', Plos Pathogens, 15, pp. e1007599, http://dx.doi.org/10.1371/journal.ppat.1007599
,2019, 'Functional cure of HIV: the scale of the challenge', Nature Reviews Immunology, 19, pp. 45 - 54, http://dx.doi.org/10.1038/s41577-018-0085-4
,2018, 'In silico investigation of the decline in clinical efficacy of artemisinin combination therapies due to increasing artemisinin and partner drug resistance', Antimicrobial Agents and Chemotherapy, 62, pp. 10.1128/aac.01292 - 10.1128/aac.01218, http://dx.doi.org/10.1128/AAC.01292-18
,2018, 'Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice', International Journal for Parasitology, 48, pp. 903 - 913, http://dx.doi.org/10.1016/j.ijpara.2018.05.010
,2018, 'Within-host modeling of blood-stage malaria', Immunological Reviews, 285, pp. 168 - 193, http://dx.doi.org/10.1111/imr.12697
,